Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

<< Previous

Bullboard Posts

Next >>

Comment by TriumphSpitSixon May 30, 2023 8:27pm

192 Views

Post# 35471394

RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

Stockhouse didn't accept my screenshot.

This should be 66%:

The interim clinical data demonstrates that 60% of Evaluable Patients (Patients evaluated by a
Principal Investigator (“PI”)) achieved a CR at 90 days post primary Study Treatment and 33%
achieved a CR at 450 days.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading